

Supporting Information For

Synthesis of new derivatives of berberine canagliflozin and study on their antibacterial activity and mechanism

Jinsheng Li^{1,2,3}, Xueli Hou^{1,2,3}, Jinlong Xiao^{2,3}, Li Zhu^{2,3}, Yujie Deng^{2,3}, Ziyi Li^{2,3}, Zijian Zhao^{1,2,3,*}, Zhenghong Luo^{2,3,*} and Hao Wei^{1,2}

¹ Department of Pharmacology, Shaanxi University of Chinese Medicine, Xianyang 712046, China; jsli1006@163.com (J.L.); xlhou199885@163.com (X.H.); weihao217@163.com (H.W.)

² School of Chemistry and Materials Science, Huaihua University, Huaihua 418000, China; jlxico0204@163.com (J.X.); lizzz082803@163.com (L.Z.); dyj20040128@163.com (Y.D.); zyli1202@163.com (Z.L.);

³ Key Laboratory of Research and Utilization of Ethnomedicinal Plant Resources of Hunan Province, Huaihua University, Huaihua 418000, China

* Correspondence: luozhenghong06@163.com (Z.L.); zzj@hhtc.edu.cn (Z.Z.)

CATALOG

Figure S 1 ¹ H NMR spectra of compound B9OC	2
Figure S 2 ¹³ C NMR spectra of compound B9OC	2
Figure S 3 MS spectra of compound B9OC	3
Figure S 4 The purity of B9OC from HPLC	3
Figure S 5 ¹ H NMR spectra of compound Berberrubine	4
Figure S 6 ¹³ C NMR spectra of compound Berberrubine	4
Figure S 7 ¹ H NMR spectra of compound Canagliflozin bromide	5
Figure S 8 ¹³ C NMR spectra of compound Canagliflozin bromide	5
Figure S 9 ¹ H NMR spectra of compound B9OBU	6
Figure S 10 ¹³ C NMR spectra of compound B9OBU	6
Figure S 11 ¹ H NMR spectra of compound BBR	7
Figure S 12 ¹³ C NMR spectra of compound BBR.....	7
Figure S 13 Western blot images for PBS-B9OC	8
Figure S 14 Western blot images for PBS-BBR-CAN-BBR+CAN	8
Figure S 15 ADMET Prediction of B9OC Based on Computer Aided	9

B90C0919/1

¹H NMR (400 MHz, Chloroform-*d*) δ 7.14 (s, 1H), 6.76 (d, *J* = 8.2 Hz, 1H), 6.59 (d, *J* = 8.4 Hz, 2H), 5.99 – 5.88 (m, 3H), 5.75 (s, 1H), 5.35 – 5.27 (m, 2H), 3.87 (s, 3H), 3.71 – 3.59 (m, 1H), 3.48 (dt, *J* = 11.1, 4.9 Hz, 1H), 3.01 – 2.71 (m, 3H), 2.45 (dd, *J* = 16.6, 4.6 Hz, 1H).




Figure S 1 ^1H NMR spectra of compound **B9OC**

B90C0919-2C/2

¹³C NMR (101 MHz, Chloroform-*d*) δ 165.49, 150.39, 148.69, 147.63, 144.40, 140.43, 137.60, 134.72, 130.62, 129.64, 128.95, 127.47, 123.58, 119.17, 115.43, 114.91, 110.89, 108.11, 108.06, 104.89, 104.38, 103.71, 101.63, 101.22, 95.30, 77.36, 56.84, 56.42, 55.09, 47.95, 39.25, 30.62, 29.84, 28.54, 18.61.




Figure S 2 ^{13}C NMR spectra of compound B9OC





Figure S 3 MS spectra of compound B9OC

SHIMADZU
LabSolutions Analysis report

⟨Sample Information⟩

Sample : b9oca365nm
 Sample ID : 01
 Inj. Volume : 10 uL
 Acquisition Date : 2023/9/13 10:37:25

⟨Chromatogram⟩



⟨Chromatogram peak table⟩


detector A 365nm

number	retention time	peak area	height	concentration
1	9.925	353117	32886	2.743 %
2	11.986	12519188	282176	97.257 %
总计		12872305	315063	

Figure S 4 The purity of B9OC from HPLC


RB0705-2/1

¹H NMR (400 MHz, Chloroform-d) δ 9.18 (s, 1H), 7.56 (s, 1H), 7.24 (d, *J*=7.5 Hz, 2H), 6.75 (s, 1H), 6.48 (d, *J*=7.9 Hz, 1H), 6.06 (s, 2H), 4.40 (t, *J*=6.1 Hz, 2H), 3.89 (s, 3H), 3.08 (t, *J*=6.1 Hz, 2H), 2.44 (s, 1H).

Figure S 5 ¹H NMR spectra of compound **Berberrubine**


RB0705-2C/2

¹³C NMR (101 MHz, Chloroform-d) δ 150.83, 149.07, 148.14, 145.77, 132.98, 131.36, 128.22, 122.22, 120.44, 120.09, 117.59, 108.41, 104.56, 102.97, 101.86, 77.36, 56.09, 53.33, 28.65.

Figure S 6 ¹³C NMR spectra of compound **Berberrubine**


BRC0914/1

^1H NMR (400 MHz, Chloroform- δ) δ 7.46 – 7.38 (m, 2H), 7.25 – 7.11 (m, 3H), 7.08 – 6.92 (m, 3H), 6.63 (d, J = 3.6 Hz, 1H), 5.30 (s, 2H), 4.43 (s, 1H), 4.15 – 4.07 (m, 3H), 4.02 (d, J = 12.4 Hz, 1H), 3.69 – 3.56 (m, 4H), 3.44 (dd, J = 8.7, 3.3 Hz, 2H), 3.07 (d, J = 3.7 Hz, 1H), 2.27 (s, 3H).

Figure S 7 ^1H NMR spectra of compound **Canagliflozin bromide**

BRC0914C/2

^{13}C NMR (101 MHz, Chloroform- δ) δ 143.05, 141.68, 138.57, 137.12, 135.95, 130.97, 130.81, 128.82, 127.26, 127.18, 126.18, 125.85, 122.85, 115.96, 115.74, 81.44, 77.72, 77.36, 75.32, 71.94, 53.58, 34.25, 33.65, 19.43.

Figure S 8 ^{13}C NMR spectra of compound **Canagliflozin bromide**

B90BU1020/1

¹H NMR (400 MHz, Chloroform-*d*) δ 10.29 (*s*, 1H), 8.36 (*s*, 1H), 7.91 (*d*, *J* = 9.0 Hz, 1H), 7.74 (*d*, *J* = 9.0 Hz, 1H), 7.36 (*s*, 1H), 6.77 (*s*, 1H), 6.04 (*s*, 2H), 5.32 (*t*, *J* = 6.3 Hz, 2H), 4.45 (*t*, *J* = 6.8 Hz, 2H), 4.01 (*s*, 3H), 3.31 (*t*, *J* = 6.3 Hz, 2H), 1.99 (*p*, *J* = 6.9 Hz, 3H), 1.57 (*q*, *J* = 7.5 Hz, 3H), 1.24 (*s*, 3H), 1.01 (*t*, *J* = 7.4 Hz, 4H).




Figure S 9 ^1H NMR spectra of compound B9OBU

B90BU1020C/2

¹³C NMR (101 MHz, Chloroform-*d*) δ 150.75, 148.39, 146.76, 137.68, 133.48, 130.62, 126.11, 123.02, 122.49, 120.38, 119.85, 108.61, 105.42, 102.22, 77.36, 75.46, 57.09, 56.21, 32.33, 29.83, 27.79, 19.22, 14.09.




Figure S 10 ^{13}C NMR spectra of compound B9OBU




Figure S 11 ¹H NMR spectra of compound BBR




Figure S 12 ¹³C NMR spectra of compound BBR




Figure S 13 Western blot images for PBS-B9OC




Figure S 14 Western blot images for PBS-BBR-CAN-BBR+CAN




Figure S 15 ADMET Prediction of B9OC Based on Computer Aided